Konstantin Zhernosekov
Garching Bei Munchen, BY, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications
[177Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.
Journal: Lancet (London, England)
Published: December 04, 2025
Safety and efficacy of [177Lu]Lu-SibuDAB in patients with progressive metastatic castration-resistant prostate cancer.
Journal: European journal of nuclear medicine and molecular imaging
Published: July 03, 2025
Biodistribution and dosimetry of [177Lu]Lu-SibuDAB in patients with metastatic castration-resistant prostate cancer.
Journal: European journal of nuclear medicine and molecular imaging
Published: September 23, 2024
Reduced Renal Uptake of Various Radiopharmaceuticals with Sodium Paraaminohippurate Coadministration in a Rat Model.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: July 15, 2024
The evolution of PRRT for the treatment of neuroendocrine tumors; What comes next?
Journal: Frontiers in endocrinology
Published: May 11, 2022
Evaluation of Safety and Dosimetry of 177Lu-DOTA-ZOL for Therapy of Bone Metastases.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: August 26, 2020
Biodistribution and dosimetry of a single dose of albumin-binding ligand [177Lu]Lu-PSMA-ALB-56 in patients with mCRPC.
Journal: European journal of nuclear medicine and molecular imaging
Published: May 21, 2020
Development of a new class of PSMA radioligands comprising ibuprofen as an albumin-binding entity.
Journal: Theranostics
Published: September 20, 2019
Development of a [177Lu]BPAMD labeling kit and an automated synthesis module for routine bone targeted endoradiotherapy.
Journal: Cancer biotherapy & radiopharmaceuticals
Published: February 26, 2015
Radiosynthesis of clinical doses of ⁶⁸Ga-DOTATATE (GalioMedix™) and validation of organic-matrix-based ⁶⁸Ge/⁶⁸Ga generators.
Journal: Nuclear medicine and biology
Published: September 01, 2014
Anti-L1CAM radioimmunotherapy is more effective with the radiolanthanide terbium-161 compared to lutetium-177 in an ovarian cancer model.
Journal: European journal of nuclear medicine and molecular imaging
Published: February 28, 2014
Folate receptor targeted alpha-therapy using terbium-149.
Journal: Pharmaceuticals (Basel, Switzerland)
Published: November 18, 2013
Last Updated: 09/26/2026